Pregledni rad
https://doi.org/10.20471/LO.2023.51.01.04
Latest perspectives on the benefits of neoadjuvant therapy for patients with advanced gastric cancer
Tea Budija
orcid.org/0009-0008-9072-2213
; School of Medicine, University of Zagreb, Zagreb, Croatia
Jasmina Marić-Brozić
orcid.org/0000-0002-5978-5960
; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia and School of Medicine, University of Zagreb, Zagreb, Croatia
Sažetak
Treatment for gastric cancer has multiple approaches and options across the world. Standard treatment for the Asian population comprises D2-gastrectomy and adjuvant chemotherapy. However, in Europe and North America, clinical trials have shown that perioperative chemotherapy, given to patients before surgery, could improve resection and survival rates significantly. Most recent studies have also discussed the advantages of doublet vs. triplet chemotherapy regimens. Furthermore, researchers have been comparing the effects of perioperative chemoradiotherapy as opposed to chemotherapy alone. The specific advantages of previously stated therapy options, as well as any novel treatments, should be researched more thoroughly in the future.
Ključne riječi
gastric cancer; screening; neoadjuvant therapy; docetaxel
Hrčak ID:
305507
URI
Datum izdavanja:
27.5.2023.
Posjeta: 495 *